AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01553916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Study NCT01553916 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation
Study NCT03308981 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REThink therapeutic online game
Description: The REThink therapeutic online game has seven levels. Each level has various degrees of complexity, which increase as the player progresses in the game. The scenario of the game was developed based on the REBT model, such that it focuses on: a. identifying the emotional and behavioral reactions; b. identifying cognitive processes; c. identifying the relation between cognitive processes and emotions and behavioral reactions; d. changing irrational cognitions into rational cognitions; e. building problem solving skills; f. building relaxation skills and g. building happiness skills.
Study NCT03308981 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: REBE group
Description: In the Rational-Emotive-Behavioral Education (REBE) group participants will follow 7 modules, structured based on the strategies practiced in each of the REThink level.
Study NCT05753280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Patients take 800 mg vitamin D capsules daily during the whole treatment period
Study NCT04372290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: Nicorette® White Ice Mint 2 mg nicotine gum
Study NCT04372290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: CSD1904-01, a nicotine pouch, 2 mg nicotine
Study NCT01982773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Hope Box Smartphone App
Description: Smartphone app
Study NCT01982773 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Treatment as Usual
Description: Printed materials
Study NCT02263482 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: control
Description: No intervention during the 8-weeks period of the study because of awaiting evaluation for cardiac rehabilitation or transplantation
Study NCT02263482 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: moderate-intensity group
Description: Patients will be submitted to a 8-weeks training program with inspiratory muscle trained at 30% of the maximal inspiratory pressure (30 minutes/session/7 days/week) + peripheral muscle trained with exercises of upper limbs and lower limbs (50% 1 RM, increased every 2-weeks).
Study NCT02263482 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low-intensity group
Description: Patients will be submited to a 8 weeks training program, with inspiratory muscle trained at 15% of the maximal inspiratory pressure (30 minutes/session/7 days/week) + peripheral muscle trained with exercises of upper limbs and lower limbs (0,5 kg each)
Study NCT03850327 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIOMONITOR III
Description: Patients with ICM indication receive a third-generation implantable cardiac monitor
Study NCT02332811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevelamer carbonate 800mg
Description: Pharmaceutical form:tablet~Route of administration: oral
Study NCT02332811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevelamer carbonate 2.4 g
Description: Pharmaceutical form:powder~Route of administration: oral
Study NCT02803385 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continous Epidural Analgesia
Description: continuous epidural infusion at rate of 5-8 ml /hr based on maximum allowable safe dose as per body weight. The pump settings will be set at 0.1 ml per bolus with lockout interval of 20 minutes. Cross over to other group will occur after 36hours.
Study NCT02803385 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Controlled Epidural Analgesia
Description: patient controlled epidural analgesia in form of Patient Controlled Analgesia pumps with continuous rate of 5-8ml/hour \& demand dose of 2-3 ml p.r.n with a lock out interval of 20 minutes based on maximum allowable safe dose as per body weight .The group will have a cross over at 36 hours postop.
Study NCT04161664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel and Carboplatin
Description: 6 courses of Paclitaxel 175 mg/m2 and Carboplatin AUC 5 in a 3 weekly schedule
Study NCT01818713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2B3-101
Description: 50 mg/m2 2B3-101 intravenous 3-weekly administration
Study NCT05049538 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood and tissue samples
Study NCT05049538 — intervention group
Intervention type: PROCEDURE
Intervention: Liquid Biopsy
Description: Undergo liquid biopsy
Study NCT02141009 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Prevnar 13
Study NCT05049538 — intervention group
Intervention type: OTHER
Intervention: Pap Smear
Description: Undergo Pap smear
Study NCT04510454 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal and throat/oropharyngeal swabs analyses by RT-PCR and ddPCR
Description: Nasopharyngeal and throat/oropharyngeal swabs analyzed by both RT-PCR and ddPCR
Study NCT03548129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phosphomycin
Description: Single dose 3 gm oral fosfomycin will be taken by mouth on an empty stomach
Study NCT03548129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Culture specific antibiotic therapy
Description: Culture-specific antibiotic treatment for 5 days
Study NCT02176590 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Power PATH
Description: PATHS: Teacher-led classroom curriculum promoting a positive classroom environment and teaching social-emotional skills
Study NCT01390805 — intervention group
Intervention type: DRUG
Intervention: Valaciclovir Hydrochloride.
Study NCT02176590 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Head Start as usual
Description: Standard Head Start programming (including classroom instruction, meals, and family services)
Study NCT04515043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INVAC-1 given in the previous phase 1 NCT02301754. No new injection is required in this study.
Description: blood sampling will be drawn once in order to analyse long term memory immune response to INVAC-1 vaccine
Study NCT03548129 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pre-treatment Urine Culture
Description: Mid-stream urine sample will be cultured and number of CFU per mL will be determined.
Study NCT03548129 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Antimicrobial sensitivity testing
Description: Susceptibility of urinary pathogens to various antimicrobials
Study NCT03548129 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Post-treatment urine culture
Description: Mid-stream urine sample will be cultured and number of CFU per mL will be determined.
Study NCT04621578 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: HANS 100B stimulator (4 conductors, 8 electrodes; Jisheng Co., Nanjing, China)
Description: Stimulation sites: Mastoid area on the contralateral side of the operation, Fengchi acupoint on the contralateral side of the operation, and Neiguan acupoints on both sides.~Timing of stimulation: In postanesthesia care unit (PACU) after extubation, 6 hours, 24 hours, 48 hours, and 72 hours after returning to the ward. 30-minutes treatment for each time-point.
Study NCT04621578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HANS 100B stimulator (4 conductors, 8 electrodes; Jisheng Co., Nanjing, China)
Description: Stimulation sites: Mastoid area on the contralateral side of the operation, Fengchi acupoint on the contralateral side of the operation, and Neiguan acupoints on both sides.~Timing of stimulation: In postanesthesia care unit (PACU) after extubation, 6 hours, 24 hours, 48 hours, and 72 hours after returning to the ward. 30-minutes treatment for each time-point.
Study NCT01624753 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: confocal microscopy
Description: During bronchoscopy, one side of the bronchial tree will be examined (either right or left) and targeted based on pre-procedure HRCT/CT scan findings. A 1.4mm diameter Alveoflex Confocal MiniprobeTM (MaunaKea Technologies, France) will be deployed down the working channel of the standard bronchoscope and advanced distally into the alveoli. Images are acquired by gentle contact providing real-time imaging and microstructural detail of the alveolus which will be continuously recorded during the procedure and stored for further morphometric and cellular analyses. Up to 10 bronchoalveolar areas will be observed and the location of the corresponding lung segment will be registered according to the international bronchial nomenclature.
Study NCT01943760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tramadol
Description: The volume of the solution was adequate to maintain the concentration of 2% tramadol
Study NCT01943760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tramadol
Description: The volume of the solution was adequate to maintain the concentration of 2% tramadol
Study NCT01943760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% saline
Study NCT01943760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% saline
Study NCT02961686 — intervention group
Intervention type: RADIATION
Intervention: Patients affected by prostate cancer
Description: Patients affected by prostate cancer and treated with a multidisciplinary approach: it includes exclusive radiotherapy, psychological and andrologic evaluation.
Study NCT05992272 — intervention group
Intervention type: BIOLOGICAL
Intervention: fMRI imaging (BOLD)
Description: Will be used to investigate neural correlates of PIT effects by measuring the blood oxygenation level dependent (BOLD) response of neural activation in the mesolimbic system.
Study NCT05992272 — intervention group
Intervention type: BIOLOGICAL
Intervention: sMRI (structure)
Description: Will be used to investigate neural correlates of PIT effects by identifying abnormalities in cortical gray and white matter volume.
Study NCT05992272 — intervention group
Intervention type: BEHAVIORAL
Intervention: Trier Social Stress Test
Description: Will be used to assess the effect of acute stress induction on behavioral and neural PIT effects. The induced stress is generated in a social context, where the participants are asked to prepare a job interview for their dream job and to present it in front of a three-member jury.
Study NCT05992272 — intervention group
Intervention type: BEHAVIORAL
Intervention: PIT paradigm
Description: The paradigm consists of four parts:~In the first part, an instrumental learning task is completed in which subjects must learn which stimuli require a response and which do not. In the second part, a classical (Pavlovian) conditioning task is then completed in which subjects learn by passive viewing which stimuli are associated with certain amounts of money. The third part measures to which instrumental responses (learned in Part 1) are modulated by the presentation of the classically conditioned stimuli (learned in Part 2). At the same time drug-associated stimuli are presented in the background measuring to which extent they conflict with the learned instrumental behavior. In the last part, query trials are implemented in which the participants have to choose between two pictures to assess the relative cue value.
Study NCT05992272 — intervention group
Intervention type: BEHAVIORAL
Intervention: Counting Stroop task
Description: Will be used to assess interference at stimulus level. Here either one, two, three or four identical digits from 1 to 4 are shown. Number and denotation of digits are either congruent (1, 22, 333, 4444; 88 trials) or incongruent (111, 2222, 3, 4444; 88 trials). Subjects have to indicate how many digits were shown
Study NCT05992272 — intervention group
Intervention type: BEHAVIORAL
Intervention: No-go Simon task
Description: Will be used to measure interference at the response level and response inhibition. We will show arrows either pointing to the left or right. The arrow can either be shown on the left or the right side of the display. In congruent trials, direction and position are the same, whereas they differ in incongruent trials. Participants have to indicate the direction of the arrow and ignore the position.
Study NCT04144855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3474 injection
Description: This is a kind of heat shock protein (HSP90) inhibitor.
Study NCT03309787 — intervention group
Intervention type: BEHAVIORAL
Intervention: eHealth
Description: Intervention Description: The pilot comprises of five components listed below which provide access to specialty obesity care to rural obese adults, and enhance it with technology (telehealth and remote monitoring): Team-based care; medical plan, nurses, psychologists, dietician, Health coaching, Weekly coaching sessions , Messaging and Remote Monitoring
Study NCT02951390 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-definition white-light endoscopy
Description: The intervention is do not perform chromoendoscopy
Study NCT01933165 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: LipiView
Study NCT04687605 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Temporary hypercapnia
Description: Temporary daily hypercapnia for 2 hours between day 4 and 14 after SAH
Study NCT03918785 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rice germ
Description: 25 g twice a day.
Study NCT03918785 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Wheat-based supplement
Description: 25g twice a day.
Study NCT03921138 — intervention group
Intervention type: OTHER
Intervention: Histopathologic tube anomalies
Description: Assessment of prevalence of histopathologic tube anomalies (Serous Tubal Intraepithelial Carcinoma (STIC) or tumor protein 53 (p53) lesion)
Study NCT01592409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: delta-9-tetrahydrocannabinol
Description: A single cannabis cigarette (potency 12.5% THC) will be given to participants to smoke over a 10 minute period, ad lib. If the cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose.
Study NCT01592409 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single placebo cannabis cigarette (0% THC) will be given to participants to smoke over a 10 minute period, ad lib. If the cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose (as this is a double-blind study).
Study NCT01951690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: defactinib (VS-6063)
Study NCT03072641 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ProBion Clinica
Study NCT01175278 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vertebral Augmentation with Balloon Kyphoplasty
Description: Two small metal tubes will be inserted through the skin into the collapsed bone. Inflatable bone tamps (balloon catheters) will be inserted through each of these two tubes into the bone. The balloons will be inflated with a liquid that can be seen on xrays (contrast) to return the bone toward its natural shape and create a cavity. The balloons will then be deflated and removed. The cavity in the bone will be filled with bone cement to stabilize the broken backbone.
Study NCT01175278 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical Treatment
Description: Non-surgical treatment means the institution of therapies other than cancer chemotherapy and surgical treatment aimed at alleviation of back pain and restoration of decreased function associated with the patient's VCF(s).
Study NCT01591733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: Up to Eight-14 day cycles
Study NCT05992272 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Stop Signal Task
Description: Will be used to examine inhibitory control. The participants tap the left and right side of the screen to smash two falling fruits. When the fruits pass two circles, subjects are required to tap both sides of the screen. In stop trials one of the fruits turns brown (rotten), indicating the corresponding side of the screen should not be tapped.
Study NCT05992272 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood samples
Description: for genetic and epigenetic testing, especially for exploratory outcome prediction using polygenic risk scores.
Study NCT02310828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetium
Description: Capsule for oral administration contains L-cysteine 100mg
Study NCT02310828 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo capsule matching Acetium for oral administration.
Study NCT04372290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: CSD1904-02, a nicotine pouch, 4 mg nicotine
Study NCT03866252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LSD
Description: LSD administration per os
Study NCT04372290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: CSD1904-02, a nicotine pouch, 8 mg nicotine (simultaneous use of two 4 mg nicotine pouches)
Study NCT05992272 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: questionnaires for chronic stress
Description: * Perceived Stress Scale~* Social Readjustment Rating Scale~* Trier Inventory for the Assessment of Chronic
Study NCT01591733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Orally, for 10 days
Study NCT01591733 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short Course Radiation
Description: Five or ten days
Study NCT00896194 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Behavioral Treatment
Description: SBT consists of group counseling sessions where participants learn about healthy eating and physical activity. Participants are also given standard calorie goals, fat gram goals, and physical activity goals (minutes).
Study NCT00896194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Standard Behavioral Intervention + Self-Efficacy
Description: This group receives identical group intervention sessions. The goals (calories, fat grams, and physical activity minutes) are tailored to the individual's progress. Participants meet regularly with an interventionist for one-on-one lifestyle counseling.
Study NCT02589158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evotaz
Description: All participants will be administered Evotaz®) (atazanavir 300mg + cobicistat 150mg) once daily for 10 days
Study NCT02589158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezolsta
Description: All participants will be administered Rezolsta® (darunavir 800mg + cobicistat 150mg) once daily for 10 days.
Study NCT00643214 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tetrix
Description: Twice daily topical application
Study NCT00643214 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Tetrix
Description: Twice daily topical application
Study NCT05992272 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: hair samples
Description: Hair cortisol measurement (3 cm hair segments) will be used to assess chronic stress.
Study NCT05992272 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: saliva samples
Description: Assessing acute stress effects in AUD.
Study NCT05992272 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: EMA assessment
Description: We will use smartphones with additional mobile sensors (wearables), which will be used to measure physical activity, data on location (GPS), geolocation-based triggering of e-Diaries, self-reported stress reactivity, cue exposure (encounters with drug-related stimuli in real life), drug craving, impulsivity and drug consumption (priming doses, binges and continuous use of all drugs of abuse).
Study NCT05992272 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: clinical diagnostic
Description: SKID-I Interview neurocognitive and psychopathological testing
Study NCT02474810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase
Description: Alteplase for CVC dysfunction.
Study NCT00674921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cotrimoxazole
Description: cotrimoxazole 800/160 mg once daily as indicated by the start and end times of the specified arms for continued prevention of HIV-related infections
Study NCT00674921 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: starch, magnesium stearate, sodium lauryl sulphate
Study NCT01591733 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: 1-4 weeks after completion of capecitabine therapy
Study NCT01576484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Alirocumab was supplied in a pre-filled syringe and administered subcutaneously (SC) in the abdomen, thigh, or outer upper arm; REGN727(SAR236553) is an anti-PCSK9 (proprotein convertase subtilisin/kexin type 9) antibody
Study NCT01576484 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Matched to Alirocumab
Description: Placebo matched to alirocumab was supplied in a pre-filled syringe and administered subcutaneously (SC) in the abdomen, thigh, or outer upper arm; REGN727(SAR236553) is an anti-PCSK9 (proprotein convertase subtilisin/kexin type 9) antibody
Study NCT00624026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine-HCl
Description: 20 mg per day (once daily)
Study NCT01918644 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: Undergo SBRT
Study NCT02219152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranexamic acid